Kiniksa Pharmaceuticals’ (KNSA) “Outperform” Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) in a research report report published on Tuesday morning,RTT News reports. The firm currently has a $34.00 target price on the stock. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q1 2025 earnings at $0.31 EPS, Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.69 EPS, FY2026 earnings at $2.55 EPS and FY2027 earnings at $3.24 EPS.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ:KNSA opened at $19.63 on Tuesday. Kiniksa Pharmaceuticals has a 12-month low of $16.56 and a 12-month high of $28.15. The business has a 50 day moving average of $19.66 and a two-hundred day moving average of $22.55. The company has a market capitalization of $1.42 billion, a PE ratio of -140.20 and a beta of 0.32.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.35 earnings per share. Equities research analysts predict that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,092 shares of company stock worth $745,589 in the last 90 days. Insiders own 54.57% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Semanteon Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at about $551,000. China Universal Asset Management Co. Ltd. grew its stake in Kiniksa Pharmaceuticals by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after acquiring an additional 3,076 shares in the last quarter. AMI Asset Management Corp acquired a new stake in Kiniksa Pharmaceuticals in the 3rd quarter valued at about $1,281,000. Rice Hall James & Associates LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 8.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock worth $16,234,000 after purchasing an additional 49,000 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $2,438,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.